AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04686162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bae application
Description: Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~1. 5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~2. Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~3. Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~4. Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior.
Study NCT02920775 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review
Study NCT05396105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deucrictibant selected dose
Description: deucrictibant soft capsule for oral use
Study NCT05726682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445419
Description: Pharmaceutical form: cell suspension Route of administration: Intravenous (IV) injection
Study NCT05978505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 MG Oral Tablet
Description: 7 nightly doses (4mg) to commence after surgery.
Study NCT05978505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 nightly doses to commence after surgery.
Study NCT04836117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SomaSignal Test Results
Description: SomaLogic, Inc. translates patterns from 5000 protein measurements made in thousands of participants in clinical trials into validated models (SomaSignal Tests) that predict important health outcomes or correlate with established health measures. SomaLogic, Inc. has developed these protein-based tests for the detection, subtyping and prognosis of heart disease and related medical, physiological and behavioral conditions. These tests are demonstrated in large retrospective studies to provide information superior to best available alternatives.
Study NCT05684913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zn granulate stent after FGG surgery
Description: Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
Study NCT05684913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostatic agent suturing
Description: Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
Study NCT06248840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
Study NCT06248840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
Study NCT05347238 — intervention group
Intervention type: DRUG
Intervention: Dopamine
Description: Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
Study NCT05347238 — intervention group
Intervention type: DRUG
Intervention: Norepinephrine
Description: Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Study NCT06097689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab Demo 1.0
Description: Lowering of the participants blood glucose with the application of insulin to induce hypoglycaemia, followed by the application of glucose to induce hyperglycaemia and finally insulin to restore euglycemia.~During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid).
Study NCT05265923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody
Study NCT05265923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CM310
Description: IL-4Rα monoclonal antibody
Study NCT05265923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04943263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracheal Temperature
Description: Temperature measured from the endotracheal tube compared with the esophageal temperature
Study NCT06366347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK inhibitor, tablet taken orally per protocol.
Study NCT06366347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitor, tablet taken orally per protocol.
Study NCT06366347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
Study NCT05905497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
Study NCT05760976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Advanced intravenous injection of cisatracurium before the succinylcholine injection
Study NCT05036928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte distribution width (MDW）
Description: All enrolled patients will receive test with MDW.
Study NCT05133271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical hemodynamic and echocardiographic evaluation
Description: Clinical hemodynamic and echocardiographic evaluation in two stages T1 and T2, before performing the spinal anesthesia, carried out by a doctor different from the doctor in charge of the parturient in the operating room to ensure the blind hemodynamic results before the spinal anesthesia, in particular those of the passive leg raise test (PLR) :~1. T1: clinico-echographic evaluation in dorsal decubitus position (45 °) with cushion under the right buttock.~2. T2: clinico-ultrasound evaluation after performing the PLR.~   Then, clinical hemodynamic evaluation during two periods T3 and T4:~3. T3: conditioning time of the parturient in the operating room during which clinical hemodynamic monitoring is set up and the basic values of arterial pressures (systolic, diastolic and mean) and heart rate are defined.~4. T4: period after performing spinal anesthesia until clamping of the umbilical cord.
Study NCT05641285 — intervention group
Intervention type: DEVICE
Intervention: The OtoSight Middle Ear Scope
Description: The OtoSight Middle Ear Scope is intended for use as an imaging tool for real-time visualization of the human tympanic membrane and fluid or air within the middle ear space. In the presence of middle ear fluid, the OtoSight Middle Ear Scope is used to visualize the fluid density. The OtoSight Middle Ear Scope is also used to provide surface images of the ear canal and tympanic membrane. It is indicated for use in children and adults.
Study NCT06052423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
Study NCT05573204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic Acid Oral Tablet
Description: Obeticholic acid used as 10 mg tablet once daily for 6 months
Study NCT05573204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit E
Description: Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
Study NCT05324930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piscean collagen dressing
Description: Piscean collagen dressing
Study NCT05324930 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline infused dressing
Description: Saline infused dressing
Study NCT06612346 — intervention group
Intervention type: DEVICE
Intervention: Minimally Invasive Micro Trabeculostomy
Description: The MINT system is a surgical device designed to create a trabeculostomy within the eye.
Study NCT06650163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Magnetic Resonance Imaging
Description: Undergo advanced MRI
Study NCT06650163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Surgery
Description: Undergo brain surgery
Study NCT06650163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06650163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immuno-Positron Emission Tomography Scan
Description: Undergo immuno-PET
Study NCT06650163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06650163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Biopsy
Description: Undergo stereotactic image-guided biopsy
Study NCT06650163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89 Crefmirlimab Berdoxam
Description: Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
Study NCT06623214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nebulyft
Description: Micro Radiofrequency Skin Treatment Device(nebulyft)
Study NCT06765005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-K10
Description: Subcutaneous injection, once every 4 weeks
Study NCT06769204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA SPRAY
Description: 2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure
Study NCT06769204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
Study NCT06769113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 1
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT06769113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 2
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT06769113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 3
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT06768151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted CEA CAR-T
Description: Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
Study NCT06768151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted CEA CAR-T
Description: Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
Study NCT06769698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC fianlimab+cemiplimab
Description: Fixed-Dose Combination (FDC) Administered per the protocol
Study NCT05261724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
Study NCT05277636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine
Description: A dose of 125 mg racemic MDMA will be administered.
Study NCT05277636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-3,4-methylenedioxymethamphetamine
Description: A dose of 125 mg enantiomeric S-MDMA will be administered.
Study NCT06769698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered per the protocol
Study NCT06769698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered per the protocol
Study NCT05277636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-3,4-methylenedioxymethamphetamine (125 mg)
Description: A dose of 125 mg enantiomeric R-MDMA will be administered.
Study NCT05277636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-3,4-methylenedioxymethamphetamine (250 mg)
Description: A dose of 250 mg enantiomeric R-MDMA will be administered.
Study NCT06765447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemostasis with 3% NaOCl in direct pulp capping
Description: after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.
Study NCT06765447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemostasis with 3% NaOCl in direct pulp capping
Description: after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.
Study NCT06765447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemostasis with diode laser in direct pulp capping
Description: Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.
Study NCT06765447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemostasis with diode laser in direct pulp capping
Description: Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.
Study NCT06767241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive auricular vagus nerve stimulation
Description: Non-invasive transcranial direct current auricular vagus nerve stimulation (tDC-aVNS)
Study NCT06767241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care treatment for moderate to severe COVID-19
Study NCT06767241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care treatment for moderate to severe COVID-19
Study NCT06768216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indianized version of Mediterranean Diet
Description: Indo Mediterranean diet will have Carbohydrates 40-45%, fats 30-35% and proteins 15-20%. Mediterranean diet, it will be specified to use Mustard oil, use of specific fruits like orange, apple, mosambi (avoid high glycemic fruits), use more of green leafy vegetables, Use of multigrain atta (Home made- 10 kg of multigrain atta will have - 8 kg of wheat + 500g each of Ragi+Bajra+ Jowar + Chana dal flour).
Study NCT06768216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Description: Low fat diet will have 50-60% carbohydrate, 20-30% fat (with \<10% saturated fat), and 20% protein. In the Low Fat Diet group, there will be only be restriction of total fat content to less than \<30%. They can use whichever household oil, consume any fruit or vegetables, any atta and no restriction on diary or non-vegetarian diet. Along with this, both groups will be given a list of do's and dont's. In the list of Do's , it will be mentioned to Eat plenty of vegetables, Fruits, Nuts, Whole grains, Screen time of less \<2 hrs /day (According to American academy of pediatrics) and Average hours of sleep in a day for age 8-18 = 8-9 hrs (According to American academy of sleep medicine). In the dont's list, it will be mentioned to avoid Sugar, Soda, Beverages, cold drinks, processed juices, processed food, junk foods, Maida, Ice cream, Creamy Desserts, Biscuit, chips and cake.
Study NCT06768216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),
Study NCT06768216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),
Study NCT05277636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mannitol)
Study NCT04836026 — intervention group
Intervention type: DEVICE
Intervention: HF20™
Description: HF20™ will be used for CRRT
Study NCT06084819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Description: 1. Azacytidine (75mg/m2/day, days 1 to 7).~2. Cytarabine (75-100mg/m2 q12h, days 1 to 5).~3. Aclacinomycin(20mg/day, days 1,3,5).~4. Chidamide(30mg/day , days 1,4,8,11).~5. Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~6. Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)
Study NCT06084819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best-Available Therapy(BAT) Regimen
Description: 1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5).
Study NCT05887843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone + Azelastine
Description: Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril